ORIGINAL RESEARCH

Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma

Ying Wu1 | Peng-Shuo Wang2 | Ben-Gang Wang3 | Lu Xu4,5 | Wan-Xia Fang4,5 | Xiao-Fang Che4,5 | Xiu-Juan Qu4,5 | Yun-Peng Liu4,5 | Zhi Li4,5

1Department of General Practice, The First Hospital, China Medical University, Shenyang, China
2Department of Psychology, The First Hospital, China Medical University, Shenyang, China
3Department of Hepatobiliary Surgery, The First Hospital, China Medical University, Shenyang, China
4Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China
5Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China

Correspondence
Zhi Li, Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China.
Email: zli@cmu.edu.cn and Yun-Peng Liu, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China. Email: cmuliuyunpeng@hotmail.com

Funding information
This study was supported by grants from the National Natural Science Foundation of China (No. 81201801 and No. 81302023), the Basic Research Projects of Higher Education Institutions in Liaoning Province (No. LFWK201706), National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2017ZX09304025), Science and Technology Plan Project of Liaoning Province (No. 2016007010), and The Key Research and Development Program of Shenyang (No. 17-230-9-01),

Abstract
The current prognostic long noncoding RNA (LncRNA) signatures for hepatocellular carcinoma (HCC) are still controversial and need to be optimized by systematic bioinformatics analyses with suitable methods and appropriate patients. Therefore, we performed the study to establish a credible LncRNA signature for HCC outcome prediction and explore the related mechanisms. Based on the LncRNA profile and the clinical data of carefully selected HCC patients (n = 164) in TCGA, six of 12727 LncRNAs, MIR22HG, CTC-297N7.9, CTD-2139B15.2, RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8 were identified as the independent predictors of patients’ overall survival in HCC by sequential univariate Cox and 1000 times Cox LASSO regression with 10-fold CV, and multivariate Cox analysis with 1000 times bootstrapping. In the Kaplan-Meier analysis with patients trichotomized by the six-LncRNA signature, high-risk patients showed significantly shorter survival than mid- and low-risk patients (log-rank test $P < 0.0001$). According to the ROCs, the six-LncRNA signature showed superior predictive capacity than the two existing four-LncRNA combinations and the traditional prognostic clinicopathological parameter TNM stage. Furthermore, low MIR22HG and CTC-297N7.9, but high CTD-2139B15.2, RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8, were, respectively, demonstrated to be related with the malignant phenotypes of HCC. Functionally, the six LncRNAs were disclosed to involve in the regulation of multiple cell cycle and stress response-related pathways via mediating transcription regulation and chromatin modification. In conclusion, our study identified a novel six-LncRNA signature for resectable HCC prognosis prediction and indicated the underlying mechanisms of HCC progression and the potential functions of the six LncRNAs awaiting further elucidation.

KEYWORDS
biomarker, hepatocellular carcinoma, LncRNA, prognosis
Hepatocellular carcinoma (HCC), accounting for 70% to 90% of primary liver cancer, is the fifth most common malignancy and the second leading cause of cancer death worldwide.1-3 Although great progress has been made on the diagnosis, treatment, and prognosis dictation of HCC, the clinical outcome is still unsatisfied.3,4 The declaration of prognostic biomarkers might be helpful for the optimization of treatment and thus the improvement of patients’ prognosis.2 Nonetheless, HCC, unlike for other tumor types, is a special disease with two competing death causes including cirrhosis and cancer, the combination of which decides the variations of HCC biological progression and makes the prognosis prediction highly complex.2,5-8 The identification of prognostic biomarkers should be integrated with the analysis of cancer stage, and the general status of both host patients and underlying liver.5,7 Besides tumor extents such as tumor size, grade, and stage, it is believed that liver fibrosis and function level, patients’ performance status, and postsurgical residual status are essential, and AFP and hepatitis activities are additional indicators for HCC prognosis.2,5,7,9

The development of high-throughput sequencing techniques and bioinformatics methods has disclosed the potential prognostic value of genomic biomarkers including long noncoding RNAs (lncRNAs).10 LncRNAs are a class of noncoding RNAs with lengths longer than 200 nucleotides, show no capacity of protein coding, but might regulate gene expression at genetic and epigenetic levels.11 So far, variety of lncRNAs or lncRNA groups have been uncovered might dictate HCC prognosis by multiple studies,10,12-17 most of which are about the functional roles and working mechanisms of single lncRNAs,14-16 and totally two (by Wang et al in 2017 and Ma et al in 2018) are found to describe the prognostic significance of multiple-lncRNA signature in HCC.13,17 However, we should be wary of the conclusions of the previous studies for the following reasons.

First, most previous studies screened out survival related lncRNAs based on the differential profile between cancer and noncancerous samples.12-16 The method could miss considerable survival information in The Cancer Genome Atlas (TCGA) datasets including some important prognostic genes,18 and lncRNAs as well. Second, most researchers did not perform preanalysis case selection,13,16,17 whereas using an uncurated TCGA dataset without attention to sample characteristics can lead to false associations and undermine the application of the conclusions.19 The patients with the diagnosis of non-HCC liver cancer (cholangiocarcinoma), pathological metastasis, and postsurgical residual carcinoma, the history of neoadjuvant treatment, and too short survival time are considered to have distinct biological procedures and progression mechanisms, and should be excluded from the prognostic analysis.8,19,20 Third, most studies performed the analysis by mixing resectable and unresectable cancers.13-17 While resectable and unresectable HCCs are demonstrated to have entirely distinct prognosis and recommended with

**FIGURE 1** Analysis of flowchart illustrates the exploration procedure for the HCC prognostic lncRNAs and the related mechanisms
completely different treatment strategies and staging systems (the Union for International Cancer Control (UICC)/the American Joint Cancer Committee (AJCC) vs the Cancer of the Liver Italian Program (CLIP)/the Barcelona Clinic Liver Cancer (BCLC)), thus should be analyzed distinctively for the development of prognostic models. Fourth, most published prognostic IncRNAs and the two established four- IncRNA signatures were identified without evaluating the relationship with other known promising HCC prognostic factors, such as the fibrosis and function levels of liver, and the performance status and serum parameters of patients, all of which are considered vital features of HCC. Fifth, the candidate prognosis-related IncRNAs in most previous studies were screened out by uni/multivariate Cox analysis, the accuracy of which is considered inferior to penalized Cox regression for small-sample and high-dimensional data.

In the current study based on appropriate selection of patients and comprehensive analysis of genetic profile and clinicopathological parameters (CPPs), we develop a novel six- IncRNA signature that could well predict patients’ prognosis in resectable HCC by combining integrated bioinformatics tools with multiple gene-profiling datasets. According to the receiver operating characteristics (ROCs), the six- IncRNA signature shows better prediction accuracy than the previously discovered IncRNA groups and the traditional prognostic tumor-node-metastasis (TNM) stage. Subsequent gene set enrichment analysis (GSEA), gene-set- IncRNA network construction, and Gene Ontology-molecular function (GO-MF) assays for IncRNA-related mRNAs disclose that these IncRNAs are involved in the vital processes associated with HCC progression. The results may enrich our knowledge on the progression mechanisms of HCC and also present a six- IncRNA signature as the potential prognosis biomarker for resectable HCC.

2 | MATERIALS AND METHODS

2.1 | Data source and processing

The expression values of IncRNA based on the Reads Per Kilobases per Million mapped reads (RPKM) were downloaded from the Atlas of Noncoding RNAs in Cancer (TANRIC) in TCGA Liver Hepatocellular Carcinoma.

**FIGURE 2** The seed IncRNAs were extracted by 1000 times Cox LASSO regression. A, Highly consistency was demonstrated in the IncRNAs among the 11 extracted IncRNA sets. The left ordinate indicates the seed IncRNA set and the number of seed IncRNAs found by every single iteration of LASSO. The right ordinate is the frequency of the seed IncRNA set disclosed through the 1000 times Cox LASSO regression. The horizontal ordinate is the IncRNA name. The yellow block represents the occurrence of the particular IncRNA in the specific IncRNA set; B, Totally 14 seed IncRNAs with >600 occurrences in the most common IncRNA set were filtered out for further analysis. The blue column indicates the frequency of each IncRNA occurs in the most common IncRNA set.
The mRNA expression profile, as well as the phenotypes and prognostic data, was downloaded from the University of California Santa Cruz (UCSC) xena website (https://xena.ucsc.edu/).

All of the included cases have primary HCC, definite report of survival status, and lncRNAs’ expression values, whereas those with the diagnosis of cholangiocarcinoma, pathological metastasis, and postsurgical residual carcinoma (R1 and R2), the survival duration not longer than 30 days, and the history of neoadjuvant treatment were excluded for further analysis.

LncRNAs were selected based on the following criteria according to the expression values and the calculated median and standard deviation (SD). First, lncRNAs with nonzero values in more than 66.7% of the cases were included. Second, the median and SD of the lncRNA should be larger than 1. Third, the lncRNAs were ranked by SDs and those with the SD larger than the median of SDs were included.

### 2.2 Cox survival analysis and least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation

The prognostic value of each lncRNA was firstly calculated in the univariate Cox analysis using R/survival package, and the lncRNAs with $P < 0.01$ were selected as seed lncRNAs for Cox LASSO regression with 10-fold cross-validation (CV).

LASSO is the penalized regression that uses an L1 penalty to shrink regression coefficients toward zero, thereby eliminate a number of variables based on the principle that the larger the penalty the fewer predictors selected. Thus, the seed lncRNAs with nonzero coefficients were considered as potential prognostic predictors. By 1000 iterations of Cox LASSO regression with 10-fold CV using the R package glmnet (with the default parameter “standardize = T”), the seed lncRNAs were shrunk into multiple-lncRNA sets. The lncRNA sets including lncRNAs with nonzero coefficients were potential prognostic models, whereas those with no lncRNA showing nonzero coefficients were designated as “not available (NA)” for prognostic prediction. The potential prognostic lncRNAs in the most common prognostic lncRNA set and with at last 600 occurrences were applied into further analysis.

To identify the prognostic value of the lncRNAs, multivariate Cox regression with 1000 times bootstrapping was further performed using R/survival package based on each “significant” lncRNA disclosed in the above steps, and the AJCC TNM stage was used as the adjustment factor. A lncRNA with $P < 0.05$ was defined as significant. The corresponding hazard ratio (HR), 95% confidence interval (CI), and $P$ value were collected.

### Table 1

| Hg19_name | Lnc ID | Ensembl_ID | Havana_gene | Gene_type | Chr | Start | End | Strand |
|-----------|--------|------------|-------------|-----------|-----|-------|-----|--------|
| MIR22HG   | ENSG00000186594.8 | OTTHUMG00000132197.5 | lincRNA | chr17 | 1614805 | 1620468 | −   |
| lnc‐BASP1‐1 | ENSG00000248223.1 | OTTHUMG00000161870.1 | lincRNA | chr5 | 17354019 | 17355008 | +   |
| lnc‐TMEM220‐1 | ENSG00000264016.2 | OTTHUMG00000178048.3 | lincRNA | chr17 | 10644584 | 1067233 | −   |
| RP11‐589N15.2 | ENSG0000002689996.1 | OTTHUMG0000084972.1 | sense_intronic | chr1 | 12113256 | 12113458 | +   |
| RP11‐479G22.8 | ENSG000002757038.1 | OTTHUMG0000082620.1 | lincRNA | chr10 | 3317069 | 3317069 | +   |
2.3 Kaplan-Meier (K-M) and ROC(t) curves with the novel-identified lncRNA signature

Based on the afore-established multivariate Cox model, the prognostic-lncRNA linear predictor of each patient was calculated based on the value of coefficient and the expression level of the corresponding covariate: linear predictor = 0.79 × EXPRESSIONMIR22HG  + 1.05 × EXPRESSIONCTD‐2139B15.2 + 0.73 × EXPRESSIONCTC‐297N7.9 + 1.16 × EXPRESSIONRP11‐589N15.2  + 1.10  × EXPRESSIONRP11‐343N15.5 + 1.12 × EXPRESSIONRP11‐479G22.8. To confirm the prognostic significance of the candidate lncRNA signature, patients were trichotomized into three groups based on the prognostic-lncRNA linear predictor (cutoff values: 33.33 and 66.67 quantile), and then, the K-M curve was plotted, and the log-rank test was calculated.

Furthermore, we calculated the resulting area under the curve (AUC) every year based on the time-dependent ROC curves using previously reported method24,25 and plotted the AUC (t) curves to compare the prediction accuracy of our candidate lncRNA prediction model with the other two published multiple-lncRNA combinations and the traditional CPPs. The traditional CPPs with missing values above 25% were excluded, while the CPPs with enough available data (age, sex, grade, and TNM stage) were firstly evaluated for the prognostic significance using K-M curve and log-rank test, and the statistically significant one (TNM stage) was applied for further study.
Correlation analysis between each lncRNA and CPPs

The associations of each lncRNA with the CPPs were further analyzed in patients with available data. For the categorical variables, such as sex, Eastern Cooperative Oncology Group Performance Status Score (ECOG PS), risk factor, Child-Pugh grade, ISHAK score, tumor grade, T classification, and TNM stage, Spearman correlation analysis, Wilcoxon sum rank test or Kruskal-Wallis test was used as appropriate. For the continuous variables including age, body mass index (BMI), tumor weight, and the serum level of alpha-fetoprotein (AFP), albumin (ALB), creatinine, platelet (PLT), and prothrombin time (PT), Pearson correlation analysis was used. Furthermore, Benjamini-Hochberg procedure was used to control the false discovery rate (FDR). P < 0.05 and FDR <0.3 was defined as statistically significant.

Because of the dimension inconsistency in source data of ALB and creatinine, we used adjusted values for the further analysis, and the adjusted values were calculated as follows: ALB_{average} = (upper limit of normal value + lower limit of normal value)/2, ALB_{adjust} = (ALB_{measure}−ALB_{average})/ALB_{average}, creatinine_{adjust} = (creatinine_{measure}−creatinine_{average})/creatinine_{average}.

GSEA and gene-set-lncRNA network construction with each of the lncRNAs

Based on the mRNA profile of the 20,530 genes downloaded from UCSC database, GSEA was performed by the JAVA program (https://www.broadinstitute.org/gsea) to identify the lncRNA-related gene sets using MSigDB H: hallmark gene sets as functional gene sets and the expression level of each lncRNA as phenotype. After performing 1000 permutations, the first 20 gene sets with FDR q < 0.25 and P < 0.05 were considered to be significantly enriched. The gene-set-lncRNA network and the corresponding heat map were then constructed with R/igraph and R/heat map package.
2.6 | IncRNA-related mRNA extraction and GO-MF analysis

To predict the molecular function of each candidate IncRNA, IncRNA-related mRNAs were firstly filtered out by Pearson correlation analysis with TCGA dataset (P- and FDR q-value < 0.001) and then applied into further GO-MF analysis using the Bioconductor “clusterProfiler” package with the statistical significance standard of P- and FDR q-value < 0.05.

3 | RESULTS

3.1 | Basic characteristics of patients

The analysis procedure of the current study is shown in Figure 1. The basic characteristics of the patients are listed in Table S1. In TCGA dataset, there were totally 164 HCC patients with the available data (Table S2) for the further analysis. Most patients were male (65.9%), in relatively good PS (PS 0:49.2%) and have tumors with Child-Pugh Grade A (47.6%), minimal fibrosis (ISHAK score 0:30.5%), Grade 2 (47.6%), T3-4 (32.3%), and TNM I stage (T1N0M0, 39.0%). The median age, BMI, tumor weight, serum AFP, ALB_adjust, creatinine_adjust, PLT, and PT of patients were 62, 25.1, 240, 13, −0.05, −0.05, 211, and 1.1, respectively, and the deaths occurred in the current cohort were 74 (45.1%).

3.2 | Identification of six key IncRNAs for HCC patients' survival

Totally, 12,727 IncRNAs were analyzed for the prognostic significance in univariate Cox survival analysis, and 30 IncRNAs with P < 0.01 were filtered out and applied to 1000 times Cox LASSO regression with 10-fold CV. As shown in Figure 2A, totally 11 IncRNA groups were disclosed, and the highly consistency among the IncRNA
sets was demonstrated. In the most common IncRNA set, 14 IncRNAs were uncovered to have >600 occurrences and extracted for further analysis (Figure 2B). The multivariate Cox analysis with 1000 times bootstrapping based on the 14 IncRNAs finally identified six IncRNAs, including MIR22HG, CTC-297N7.9, CTD-2139B15.2, RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8, to be the independent predictors of patients’ survival in HCC. The detailed information and the survival significance of the six IncRNAs are shown in Tables 1 and 2.

**FIGURE 4** The significant trends in the associations of MIR22HG, CTD-2139B15.2, and CTC-297N7.9 expression with clinicopathological characteristics of the cohort. Low level of MIR22HG significantly indicated advanced T classification (A) and higher Child-Pugh score (B) of HCC patients. Higher CTD-2139B15.2 predicted higher ECOG PS score (C) and tumor grade (D). CTC-297N7.9 was associated with low ECOG PS score of patients (E), the low grade (F), and early T classification (G) and TNM stage (H) of tumors, and the low serum levels of ALB (I). For categorical variables, the data distributions of each IncRNA were illustrated by the box plots. In the plot, the upper and lower hinge and the inner line of the boxes indicate the first and third quartile and the median value of the data, respectively, and the black dots represent the outlier values. For continuous variables, we used scatter plot with trend line illustrating their relationships with the level of each IncRNA.
According to the K-M analysis (Figure 3A), there is a significant difference in patients’ survival among high-, mid-, and low-risk groups divided by the six-lncRNA signature (log-rank test \( P < 0.0001 \)), and patients in the high-risk group had significantly shorter survival (median 21.3 months) than those in the mid- (median 38.3 months) and low-risk groups (median 81.9 months).

In the time-dependent ROC curve analysis (Figure 3B), the AUCs in the first, third, and fifth year are 0.830, 0.739, and 0.852, respectively, and the prediction capability of our six-lncRNA signature is superior to the two published four-lncRNA groups. Moreover, the inclusion of six-lncRNA linear predictor to the prognostic model using TNM stage obviously improved the prediction ability for survival, as demonstrated by the increase of the resulting AUC values.

The significant trends in the associations of each lncRNA expression with clinicopathological characteristics of the cohort are shown in Table 3 and Figures 4 and 5. On the one hand, we found two prognosis benefit lncRNAs. MIR22HG was demonstrated to be negatively correlated with T classification (\( P = 0.0381 \)) and Child–Pugh score (\( P = 0.0135 \)) of HCC (Figure 4A,B), and CTC-297N7.9 was negatively associated with ECOG PS of patients (\( P = 0.0444 \)), the grade (\( P = 0.0059 \)), T classification (\( P = 0.0216 \)), and TNM stage (\( P = 0.0087 \)) of tumors, and the serum levels of ALB (\( P = 0.0121 \)) (Figure 4E-I). On the other hand, four lncRNAs majorly indicated malignant phenotypes in HCC. CTD-2139B15.2 was positively related with ECOG PS (\( P = 0.0023 \)) and grade (\( P = 0.0004 \)) (Figure 4C and

### FIGURE 5
The analysis for the significant trends in the relationships between the levels of RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8 and the clinicopathological parameters of the HCC cohort. RP11-589N15.2 was higher in male patients (A). RP11-343N15.5 significantly predicted advanced T classification (B) and TNM stage (C) of HCC. Patients with advanced tumor grade (D), T classification (E), and TNM stage (F) expressed higher RP11-479G22.8. For categorical variables, the data distributions of each lncRNA were illustrated by the box plots. In the plot, the upper and lower hinge and the inner line of the boxes indicate the first and third quartile and the median value of the data, respectively, and the black dots represent the outlier values.
D). RP11-589N15.2 was observed higher in male patients ($P = 0.0317$) (Figure 5A), and RP11-343N15.5 significantly predicted advanced T classification ($P = 0.0196$) and TNM stage of HCC ($P = 0.0087$) (Figure 5B,C). The significant positive relationships were disclosed between RP11-479G22.8 levels and the tumor grade ($P = 0.0430$), and
T classification \((P = 0.0160)\), and TNM stage \((P = 0.0211)\) (Figure 5D-F).

### 3.4 Elucidation for the functional roles of the six key lncRNAs

For each lncRNA, multiple significant gene sets were extracted by GSEA based on FDR q-values (Table 4) and illustrated by both network and heat map (Figure 6A and B). Low levels of MIR22HG and CTC-297N7.9, but high levels of RP11-343N15.5, were significantly enriched with cell cycle or DNA repair-related gene sets, such as E2F_TARGETS, G2M_CHECKPOINT, MITOTIC_SPINDLE, DNA_REPAIR, MYC_TARGETS. However, high expressions of CTD-2139B15.2 and RP11-589N15.2 were found to enrich the gene sets related with cell homeostasis or stress response, such as P53_PATHWAY, MITORC1_SIGNALING, MYC_TARGETS_V1 and V2, UNFOLD Protein Response, Reactive_OxigensSpecies_PATHWAY, UV_RESPONSE_UP, and so on. In the Pearson correlation analysis of the key lncRNAs with mRNAs using TCGA profile, there were, respectively, 12, 784, 55, 8, 240, and 186 genes closely related with MIR22HG, CTC-297N7.9, CTD-2139B15.2, RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8. According to further GO-MF analysis for the specific lncRNA-related mRNAs, we supposed that RP11-479G22.8 took part in the modifications of “oxidoreductase activity,” “cofactor binding,” and “C-acyltransferase activity” (Figure 7A); RP11-343N15.5 played key roles in tubulin/nucleosome/microtubule binding and “microtubule motor activity” (Figure 7B); CTD-2139B15.2 potentially functioned in “ligase activity” and “magnesium ion binding” (Figure S1A); and CTC-297N7.9 majorly involved in the cofactor/chromatin/NAD binding and the oxidoreductase/DNA-dependent ATPase activity (Figure S1B). Detailed information of the top five GO-MF terms based on \(P\) values is listed in Table 5.

### 4 DISCUSSION

By applying multiple biostatistics methods, such as univariate Cox and 1000 times Cox LASSO regression with 10-fold CV and multivariate Cox analysis with 1000 times bootstrapping, on the overall lncRNA data of appropriately selected cases in TCGA, six lncRNAs, MIR22HG, CTC-297N7.9, CTD-2139B15.2, RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8, were currently filtered out and identified as the independent prognosis predictors in HCCs. The prognostic significance, the prediction superiority, and the clinicopathological roles of the six-lncRNA signature were, respectively, confirmed by K-M analysis, time-dependent ROC curves,
LncRNAs are considered to have greater potentiality than other hallmarks of cancers as the biomarkers of diagnosis and prognosis because of following unique advantages. (a) The expressions of lncRNAs show great divergence in different tissues, diseases and the disease progression stage, thus are more representative of disease characteristics.\textsuperscript{26,27} (b) LncRNAs are noncoding RNAs and directly involve in various biological processes, thus the levels and functions are more closely associated with the development characteristics of diseases including cancers.\textsuperscript{28-31} Therefore, more and more studies are performed to clarify the clinical significance of lncRNAs in cancers, including HCCs.

Although more and more lncRNAs have been identified involved in various diseases including cancers, the functions of most lncRNAs are still not well understood, and a large number of lncRNAs are awaiting further characterizations. Accordingly, it is popular to predict the functions of lncRNAs by GSEA, GO-MF, and lncRNA-mRNA coexpression analysis.\textsuperscript{32,33} With these popular methods, the six lncRNAs were currently unraveled to potentially involve in multiple ontogenetic mechanisms, such as cell cycle, DNA repair, cell homeostasis, and stress response, via variety of functions including “ligase activity,” “magnesium ion binding,” cofactor/chromatin/NAD binding, oxidoreductase/DNA-dependent ATPase activity, tubulin/nucleosome/microtubule binding, “microtubule motor activity,” and “C-acyltransferase activity,” which were regarded fundamental for transcription regulation and chromatin modification, and important for HCC development and progression.\textsuperscript{2,30,31}

On the one hand, MIR22HG and CTC-297N7.9 are found to predict better prognosis of HCCs among the six lncRNAs, and these results could be well supported by their negative relationships with the advanced CPPs revealed in the current study and are consistent with the previous studies of MIR22HG in HCCs and lung adenocarcinomas and CTC-297N7.9 in HCCs.\textsuperscript{13,34,35} Functionally, we demonstrate the involvement of MIR22HG in cell cycle and DNA repair pathways, and thus present further bioinformatics evidence for the recent observations that MIR22HG prohibits the proliferation of liver cancer cells and inhibits cell cycle-related genes via the regulation of YBX1, Met, and P21 in lung cancer.\textsuperscript{35,36}
TABLE 5  GO-MF assays according to the levels of the six-lncRNA-related mRNAs in TCGA

| ID          | Description                                                                 | GeneRatio | BgRatio     | P            | P adjust    | Q            | Count |
|-------------|-----------------------------------------------------------------------------|-----------|-------------|--------------|-------------|--------------|-------|
| CTD-2139B15.2a | Aminoacyl-tRNA ligase activity                                              | 4/46      | 44/16982    | 5.91E−06     | 0.00041374  | 0.0003102   | 4     |
| GO:0016875   | Ligase activity, forming carbon-oxygen bonds                                | 4/46      | 44/16982    | 5.91E−06     | 0.00041374  | 0.0003102   | 4     |
| GO:0016876   | Ligase activity, forming aminoacyl-tRNA and related compounds              | 4/46      | 44/16982    | 5.91E−06     | 0.00041374  | 0.0003102   | 4     |
| GO:0016874   | Ligase activity                                                             | 6/46      | 177/16982   | 7.81E−06     | 0.00041374  | 0.0003102   | 6     |
| GO:0000287   | Magnesium ion binding                                                       | 5/46      | 196/16982   | 0.0001816    | 0.00770244  | 0.00577491  | 5     |
| CTC-297N7.9a | Cofactor binding                                                            | 50/714    | 264/16982   | 1.72E−19     | 1.26E−16    | 1.10E−16    | 50    |
| GO:0016614   | Oxidoreductase activity, acting on CH-OH group of donors                    | 27/714    | 137/16982   | 1.55E−11     | 3.80E−09    | 3.29E−09    | 27    |
| GO:0003682   | Chromatin binding                                                           | 46/714    | 482/16982   | 1.91E−07     | 2.50E−05    | 2.16E−05    | 46    |
| GO:0051287   | NAD binding                                                                 | 13/714    | 53/16982    | 2.04E−07     | 2.50E−05    | 2.16E−05    | 13    |
| GO:0008094   | DNA-dependent ATPase activity                                               | 15/714    | 76/16982    | 5.10E−07     | 5.34E−05    | 4.63E−05    | 15    |
| RP11-343N15.5 | Tubulin binding                                                            | 12/214    | 289/16982   | 0.00031283   | 0.04698072  | 0.04389422  | 12    |
| GO:0031491   | Nucleosome binding                                                          | 5/214     | 49/16982    | 0.00036839   | 0.04698072  | 0.04389422  | 5     |
| GO:0003777   | Microtubule motor activity                                                  | 6/214     | 77/16982    | 0.00042041   | 0.04698072  | 0.04389422  | 6     |
| GO:0008017   | Microtubule binding                                                         | 10/214    | 217/16982   | 0.0004401    | 0.04698072  | 0.04389422  | 10    |
| RP11-479G22.8a | Oxidoreductase activity, acting on the CH-NH group of donors                | 7/170     | 28/16982    | 8.83E−09     | 3.72E−06    | 3.18E−06    | 7     |
| GO:0048037   | Cofactor binding                                                            | 14/170    | 264/16982   | 4.39E−07     | 9.24E−05    | 7.90E−05    | 14    |
| GO:0016614   | Oxidoreductase activity, acting on CH-OH group of donors                    | 10/170    | 137/16982   | 1.19E−06     | 0.00012535  | 0.00010719  | 10    |
| GO:0016408   | C-acyltransferase activity                                                  | 4/170     | 20/16982    | 4.14E−05     | 0.00249223  | 0.00213112  | 4     |
| GO:0016903   | Oxidoreductase activity, acting on the aldehyde or oxo group of donors      | 5/170     | 45/16982    | 8.38E−05     | 0.00440768  | 0.00376904  | 5     |

*The first five GO-MF terms based on P values were listed.*
Previous reports showed that CTC-297N7.9 prohibited cancer development via the transmembrane protein, and our current study discloses that CTC-297N7.9 negatively regulates the pathways of E2F_TARGETS, G2M_CHECKPOINT, and MITOTIC_SPINDLE via involving in cofactor/chromatin/NAD binding and oxidoreductase/DNA-dependent ATPase activity.

On the other hand, the other four lncRNAs, including CTD-2139B15.2, RP11-589N15.2, RP11-343N15.5, and RP11-479G22.8, are currently demonstrated to be poorer prognosis indicators for HCCs, and the reports on the prognostic roles of CTD-2139B15.2 in papillary thyroid cancer and RP11-479G22.8 in lung adenocarcinoma tally with the findings, whereas there is no previous report on the clinicopathological relevance of RP11-589N15.2 and RP11-343N15.5 in cancers. Moreover, the harmful roles of the four lncRNAs in cancers is unknown. For the first time, we uncovered the involvement of CTD-2139B15.2 in cell homeostasis and stress response through “ligase activity” and “magnesium ion binding” and RP11-343N15.5 in cell cycle progression via tubulin/nucleosome/microtubule binding and “microtubule motor activity,” and disclosed the roles of RP11-589N15.2 in cell homeostasis and stress response and the “oxidoreductase activity,” “cofactor binding,” and “C-acyltransferase activity” of RP11-479G22.8 in HCCs. As for the molecular functions of RP11-589N15.2 and the biological processes that involved by RP11-479G22.8, there are no statistical findings in the present study based on the current dataset, and more biostatistics analysis and molecular studies are needed.

Comparing with other studies for the prognostic roles of lncRNAs in HCCs, our study exhibits several superiorities. In the initial step, it is more sensible to identify prognostic molecules from global lncRNAs, rather than starting from differential expression ones. On the study cohort, homogeneity of patients is greatly improved by excluding the specific cases might have distinct disease procedures, such as those diagnosed as cholangiocarcinoma, received neoadjuvant therapy, survived too short durations, and had distant metastasis or residual tumors. On the study method, the accuracy of the bioinformatics analysis is increased by integrating 1000 times LASSO regression and bootstrapping, and the clinical reasonability of the biomarker study is validated by the functional analysis combining with the CPPs of cancer and the physical status of patients. As for the prediction efficacy, our six-lncRNA signature was helpful to improve the prediction accuracy of traditional prognostic TNM stage and showed superiority than the two revealed four-lncRNA groups based on the increase of the resulting AUC values in the analysis of the ROC curves. Additionally, the lncRNA SNHG20 and SERHL disclosed by Ma et al in the recently published four-lncRNA-signature study were demonstrated prognostic insignificant (P = 0.1072 and 0.1304, respectively, in univariate Cox analysis) in the current cohort of patients carefully selected based on the clinicopathological characteristics.

Several limitations should be considered. First, we did not perform in vitro and in vivo experimental studies to confirm the prognostic role of the six-lncRNA signature in HCCs, which was deduced from online datasets using bioinformatics methods. Second, there is no other available dataset so far that could be used to present more external validations for the results of the current study. Further validations are awaited.

In summary, we uncover a six-lncRNA signature as the independent prognosis biomarker in HCCs by the comprehensive bioinformatics analysis combining the genetic profile and CPPs data in carefully selected cohort, confirm its’ superior capability for resectable HCC prognosis prediction based on the ROC curves comparing with the other multiple-lncRNA combinations and the traditional CPPs, and reveal the regulation of cell cycle and stress response-related pathways via transcription and chromatin modifications as the potential functional roles of the six lncRNAs in resectable HCC progression. The results not only disclose the novel candidate biomarker for HCC outcome prediction, but also indicate the interesting topics for future studies on the underlying mechanisms of HCC progression and the potential functions of the six lncRNAs.

CONFLICT OF INTEREST

None declared.

ORCID

Zhi Li http://orcid.org/0000-0002-6437-0348

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301-1314.
3. Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017;11(4):389-398.
4. Grandhi MS, Kim AK, Ronneklev-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25(2):74-85.
5. Petrizzo A, Buonaguro L. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. J Immunother Cancer. 2016;4:71.
6. Nathan H, Mentha G, Marques HP, et al. Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford). 2009;11(5):382-390.

7. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S80-S89.

8. Brian O'Sullivan J, D'Cruz A, Fey M, Pollock RE, Vermorken J, Huang SH. Manual of Clinical Oncology, 9th edn. Hoboken, NJ: John Wiley & Sons, Inc.; 2015.

9. Bauschke A, Altenendorf-Hofmann A, Malecza S, Schule S, Zanow J, Sittmecher U. Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV? J Cancer Res Clin Oncol. 2016;142(12):2593-2601.

10. Xiao Z, Shen J, Zhang L, Li M, Hu W, Cho C. Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects. Oncol Lett. 2018;15(3):3395-3402.

11. Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2017;28:287-301.

12. Xu JH, Chang WH, Fu HW, Shu WQ, Yuan T, Chen P. Upregulated long non-coding RNA LOC90784 promotes cell proliferation and invasion and is associated with poor clinical features in HCC. Biochem Biophys Res Commun. 2017;490(3):920-926.

13. Wang Z, Wu Q, Feng S, Zhao Y, Tao C. Identification of four prognostic LncRNAs for survival prediction of patients with hepatocellular carcinoma. PeerJ. 2017;5:e3575.

14. Dai M, Chen S, Wei X, et al. Diagnosis, prognosis and bioinformatics analysis of lncRNAs in hepatocellular carcinoma. Oncotarget. 2017;8(56):95799-95809.

15. Cui H, Zhang Y, Zhang Q, Chen W, Zhao H, Liang J. A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma. Cancer Med. 2017;6(12):2932-2941.

16. Niu ZS, Niu XJ, Wang WH. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications. World J Gastroenterol. 2017;23(32):5860-5874.

17. Ma Y, Luo T, Dong D, Wu X, Wang Y. Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma. Gene. 2018;663:148-156.

18. An N, Yu Z, Yang X. Expression differentiation is not helpful in identifying prognostic genes based on TCGA datasets. Mol Ther Nucleic Acids. 2018;11:292-299.

19. Peran I, Madhavan S, Byers SW, McCoy MD. Curation of the pancreatic ductal adenocarcinoma subset of The Cancer Genome Atlas is essential for accurate conclusions about survival related molecular mechanisms. Clin Cancer Res. 2018;24(16):3813-3819.

20. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745-761.

21. Caselitz M, Masche N, Flemming P, et al. Prognosis of hepatocellular carcinoma according to new staging classifications. Dtsch Med Wochenshr. 2004;129(33):1725-1730.

22. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385-395.

23. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1-22.

24. Li Z, Yamada S, Wu Y, et al. Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection. Oncotarget. 2016;7(34):54463-54473.

25. Heagerty PJ, Zheng Y. Survival model predictable accuracy and ROC curves. Biometrics. 2005;61(1):92-105.

26. Yan X, Hu Z, Feng Y, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell. 2015;28(4):529-540.

27. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703-719.

28. Fatica A, Bozzi I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7-21.

29. Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37.

30. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.

31. Lanzafame M, Bianco G, Terracciano LM, Ng C, Piscuoglio S. The role of long non-coding RNAs in Hepatocarcinogenesis. Int J Mol Sci. 2018;19(3):682.

32. Guo X, Gao L, Liao Q, et al. Long non-coding RNAs function annotation: a global prediction method based on bi-colored networks. Nucleic Acids Res. 2013;41(2):e35.

33. Jiang Q, Ma R, Wang J, et al. LncRNA2Function: a comprehensive resource for functional investigation of human lncRNAs based on RNA-seq data. BMC Genom. 2015;16(Suppl 3):S2.

34. Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z, Zhang LW. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 2016;20(11):2285-2295.

35. Dong Y, Yan W, Zhang SL, et al. Prognostic values of long non-coding RNA MIR22HG for patients with hepatocellular carcinoma after hepatectomy. Oncotarget. 2017;8(69):114041-114049.

36. Su W, Feng S, Chen X, et al. Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncopgenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018;78(12):3207-3219.

37. Li Q, Li H, Zhang L, Zhang C, Yan W, Wang C. Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer. Oncotarget. 2017;8(28):46136-46144.

38. Wei Y, Zhang X. Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma. Tumour Biol. 2016;37(12):16275-16285.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.